ABAC Therapeutics
Barcelona
About ABAC Therapeutics
ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate early other pharmaceutical properties, such as suitable pharmacokinetics and toxicological characteristics, to maximize the chance of success in clinical development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $20.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2018)
- Website: abactherapeutics.com
- Phone: (+34) 93 230 11 54
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/abac-therapeutics-30054 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.